Simultaneous integrated radiotherapy boost to the dominant intraprostatic lesion: Final results of a phase I/II trial

Milly Buwenge, Anna Rita Alitto, Savino Cilla, Ilaria Capocaccia, Ercole Mazzeo, Edy Ippolito, Giovanna Mantini, Giambattista Siepe, Letizia Cavallini, Vincenzo Valentini, Francesco Deodato, Alessio G. Morganti, Alessio Giuseppe Morganti, Gabriella Macchia

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Background/Aim: Late toxicity and long-term outcomes of a phase I-II trial on patients with prostate cancer treated with an integrated boost to the dominant intraprostatic lesion (DIL) are reported. Patients and Methods: Patients were treated using intensity-modulated radiotherapy, with a simultaneous integrated boost to the DIL, defined on staging magnetic resonance imaging, delivering 72 Gy in 1.8 Gy/fraction to prostate/seminal vesicles and 80 Gy in 2 Gy/fraction to the DIL. The primary endpoint was acute toxicity and secondary endpoints were late toxicity and biochemical disease-free survival. Results: Forty-four patients were enrolled. The median follow-up was 120 (range=25-150) months. Five-year rates of grade 3 late gastrointestinal and genitourinary toxicity were 2.3% and 4.5%, respectively; only one grade 4 late genitourinary toxicity was recorded. Five-year biochemical relapse-free and overall survival rates were 95.3% and 95.5%, respectively. Conclusion: The treatment was well tolerated and achieved excellent results in terms of outcome in patients with low-intermediate Gleason’s score and low risk of nodal metastasis.
Lingua originaleEnglish
pagine (da-a)6499-6503
Numero di pagine5
RivistaAnticancer Research
Stato di pubblicazionePubblicato - 2020


  • Adult
  • Aged
  • Aged, 80 and over
  • Disease-Free Survival
  • Dominant intraprostatic lesion
  • Dose Fractionation, Radiation
  • Humans
  • Intensity-modulated radiotherapy
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Phase I-II
  • Prostate
  • Prostate neoplasms
  • Prostate-Specific Antigen
  • Prostatic Neoplasms
  • Radiotherapy, Image-Guided
  • Radiotherapy, Intensity-Modulated
  • Simultaneous integrated boost


Entra nei temi di ricerca di 'Simultaneous integrated radiotherapy boost to the dominant intraprostatic lesion: Final results of a phase I/II trial'. Insieme formano una fingerprint unica.

Cita questo